Inhibitec Anticuerpos is selected by the NEOTEC 2021 Grant (SNEO- 2021 1187). ‘CDTI Supported/ Subvencionado por CDTI’

We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development). This prestigious grant is designed to support the initiation of new entrepreneurial projects that leverage technology or knowledge developed from research activities, with a business strategy focused on technology development.

Our project ‘Nuevas terapias para enfermedades autoinmunes basada en el bloqueo de BAMBI’ (SNEO-20211187), will spans over 1 or 2 years (starting on January 1st, 2022), aligns perfectly with the objectives of the NEOTEC program. This project will be funded through the Mechanism for Recovery and Resilience and the “Next Generation EU” funds. As recipients, we are committed to fulfilling all obligations outlined in Regulation (EU) 2021/241 of the European Parliament and of the Council of February 12, 2021, establishing the Mechanism for Recovery and Resilience, as well as other relevant EU or national regulations leading this financing.

We extend our gratitude to CDTI for their support, and we are excited to embark on this journey of innovation and technological advancement in our industry.

Share the Post:

Related Posts

Se buscan candidatos/as interesados en desarrollar su carrera científica en la empresa Inhibitec Anticuerpos S.L., para cubrir un puesto de doctor. Inhibitec-Anticuerpos S.L. es una...

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors...

World Lupus Day was celebrated on 10th May. At Inhibitec we were very proud to share our progress on the effects of BAMBI deficiency in...

Scroll to Top